Combination Shows Promise in Relapse Prevention

According to a study published in the journal Blood, University of Manchester researchers believe that by using a chemical in conjunction with radiation therapy, they can boost the time a patient remains free of lymphoma by a factor of four, compared with radiation therapy alone.

The chemical is called R848. It sends signals to the receptors on the surface of immune cells, which excites them into action, creating an expanding pool of immune killer T-cells, thereby using the body's immune system to help fight the lymphoma. The chemical was used in unison with radiotherapy.

"Excitingly we think that this new approach to treating cancer could be capable of giving patients a better response to conventional therapies through the generation of a lymphoma-specific immune response against tumor cells," said one of the researchers, Prof. Tim Illidge.

"This could be the key to ensuring long-term survival in more patients and reducing the number of relapses after initial therapy."

Treatment not yet tested in humans

The chemical did not seem to cause any major side effects, but this experiment and these findings are the result of work done in mice, and the strategy and treatment has yet to move into the clinical phase and be tested in humans.

That said, enrolling the immune system in fighting lymphoma or any cancer is considered the gold standard, and these researchers think they may have found a way to do just that. More research will shed light on whether or not they are on to something truly promising.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap